AMAG Pharma (AMAG) Misses Q2 EPS, Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
AMAG Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Corporate Update
August 6, 2020 7:00 AM EDTFinancial guidance reissued to include EBITDA-positive projection for second-half 2020
Strategic shift and momentum build through recent business development activities
Brian Piekos promoted to Chief Financial Officer
Conference call scheduled for 8:00 a.m. ET today
WALTHAM, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the second quarter ended June 30, 2020. The company reported total revenues for the second quarter of 2020 of $52.8 million, including revenue of $29.6 million from Feraheme® (ferumoxytol injection) and... More
